<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-09-08 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products," replacing the December 2014 draft guidance of the same name. This draft guidance, once finalized, will assist sponsors of investigational new drug applications (INDs) and applicants of new drug applications (NDAs), biologics license applications (BLAs), and su...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-19410</p>
    <p><strong>Publication Date:</strong> 2022-09-08</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/09/08/2022-19410/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological">https://www.federalregister.gov/documents/2022/09/08/2022-19410/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-19410</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
